Avant reports infectious joy but humble heart news
To give the good news first, Avant revealed that it will get a $40 million royalty payment from GlaxoSmithKline now the company’s co-developed vaccine Rotarix has gained approval
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.